BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 32002591)

  • 21.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Ilhan H; Kroenke M; Wurzer A; Unterrainer M; Heck M; Belka C; Knorr K; Langbein T; Rauscher I; Schmidt-Hegemann NS; Schiller K; Bartenstein P; Wester HJ; Eiber M
    J Nucl Med; 2022 Aug; 63(8):1208-1214. PubMed ID: 35273094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-fraction prostate-specific membrane antigen positron emission tomography- and multiparametric magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer local recurrences.
    Ehret F; Hofmann T; Fürweger C; Kufeld M; Staehler M; Muacevic A; Haidenberger A
    BJU Int; 2023 Jan; 131(1):101-108. PubMed ID: 36114771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy.
    Harsini S; Wilson D; Saprunoff H; Allan H; Gleave M; Goldenberg L; Chi KN; Kim-Sing C; Tyldesley S; Bénard F
    Cancer Imaging; 2023 Mar; 23(1):27. PubMed ID: 36932416
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Artigas C; Flamen P; Charlier F; Levillain H; Wimana Z; Diamand R; Albisinni S; Gil T; Velthoven RV; Peltier A; Gestel DV; Roumeguere T; Otte FX
    World J Urol; 2019 Aug; 37(8):1535-1542. PubMed ID: 30824985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3-Year Freedom from Progression After
    Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P
    J Nucl Med; 2020 Jun; 61(6):866-872. PubMed ID: 31676727
    [No Abstract]   [Full Text] [Related]  

  • 28. Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study.
    Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Lanzafame H; Giuseppe Morganti A; Trapp C; Koerber SA; Debus J; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Ruf J; Grosu AL; Ceci F; Fendler WP; Bartenstein P; Kroeze SGC; Guckenberger M; Krafcsik M; Klopscheck C; Fanti S; Hruby G; Emmett L; Belka C; Stief C; Schmidt-Hegemann NS; Henkenberens C; Mayer B; Miksch J; Shelan M; Aebersold DM; Thamm R; Wiegel T
    Radiother Oncol; 2023 Jul; 184():109678. PubMed ID: 37146766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
    BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Marzec J; Becker J; Paulsen F; Wegener D; Olthof SC; Pfannenberg C; Schwenck J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
    Acta Oncol; 2020 Feb; 59(2):149-156. PubMed ID: 31559880
    [No Abstract]   [Full Text] [Related]  

  • 31. The use of
    Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
    BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interobserver variability, detection rate, and lesion patterns of
    Miksch J; Bottke D; Krohn T; Thamm R; Bartkowiak D; Solbach C; Bolenz C; Beer M; Wiegel T; Beer AJ; Prasad V
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2339-2347. PubMed ID: 32157427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer.
    Mohan R; Kneebone A; Eade T; Hsiao E; Emmett L; Brown C; Hunter J; Hruby G
    Radiat Oncol; 2023 Aug; 18(1):127. PubMed ID: 37528487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of relapse as determined by
    Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
    Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET/CT within a prospective study.
    Francolini G; Banini M; Di Cataldo V; Detti B; Caini S; Loi M; Simontacchi G; Desideri I; Greto D; Valzano M; Roghi M; Serni S; Vaggelli L; Salvestrini V; Visani L; Becherini C; Olmetto E; Franzese C; Baldaccini D; Scorsetti M; Sollini M; Chiti A; Meattini I; Valicenti RK; Livi L
    Prostate; 2023 Sep; 83(12):1201-1206. PubMed ID: 37290915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial multicentre experience of
    Siriwardana A; Thompson J; van Leeuwen PJ; Doig S; Kalsbeek A; Emmett L; Delprado W; Wong D; Samaratunga H; Haynes AM; Coughlin G; Stricker P
    BJU Int; 2017 Nov; 120(5):673-681. PubMed ID: 28548372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer.
    Reverberi C; Massaro M; Osti MF; Anzellini D; Marinelli L; Montalto A; De Sanctis V; Valeriani M
    Sci Rep; 2020 Oct; 10(1):17471. PubMed ID: 33060732
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Eiber M; Kroenke M; Wurzer A; Ulbrich L; Jooß L; Maurer T; Horn T; Schiller K; Langbein T; Buschner G; Wester HJ; Weber W
    J Nucl Med; 2020 May; 61(5):696-701. PubMed ID: 31836682
    [No Abstract]   [Full Text] [Related]  

  • 39. Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: Implications for potential salvage.
    Maitre P; Sood S; Pathare P; Krishnatry R; Agrawal A; Rangarajan V; Murthy V
    Radiother Oncol; 2022 Apr; 169():71-76. PubMed ID: 35189154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis.
    Schmidt-Hegemann NS; Stief C; Kim TH; Eze C; Kirste S; Strouthos I; Li M; Schultze-Seemann W; Ilhan H; Fendler WP; Bartenstein P; Grosu AL; Ganswindt U; Belka C; Meyer PT; Zamboglou C
    J Nucl Med; 2019 Feb; 60(2):227-233. PubMed ID: 30002108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.